Product Datasheet
PARK7/DJ1 Antibody
Catalog Number: 49058
Technical:tech@swbio.com
Information:info@swbio.com
Description
- Swiss-Prot No.:
- Swiss-Prot#:Q99497
- Form of Antibody:
- 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.
- Immunogen:
- recombinant protein
- appl_detail:
- WB: 1:1,000-1:2,000
IHC: 1:100-1:500
ICC: 1:100-1:500
FC: 1:50-1:100
- other_names:
- CAP1 antibody DJ-1 antibody DJ1 antibody DJ1 protein antibody Epididymis secretory sperm binding protein Li 67p antibody FLJ27376 antibody FLJ34360 antibody FLJ92274 antibody HEL S 67p antibody Oncogene DJ1 ant
- Purification:
- ProA affinity purified
- Applications:
- WB, ICC/IF, IHC, IP, FC
- Background:
- PARK7/DJ1 is a ubiquitously expressed protein involved in various cellular processes including cell proliferation, RNA-binding, and oxidative stress. The protein has been found to colocalize within a subset of pathologic tau inclusions in a diverse group of neurodegenerative disorders known as tauopathies. Defects in PARK7/DJ1 are the cause of autosomal recessive early-onset Parkinson's disease 7 (PARK7). Parkinson's disease (PD) is a complex, multifactorial disorder that typically manifests after the age of 50 years. The disease is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK7 is characterized by onset before 40 years and slow progression. It has also been suggested that PARK7/DJ1 is a mitogen dependent oncogene product involved in Ras related signal transduction pathways.
© Signalway Biotechnology All Rights Reserved.